Меню
Набор скоро начнётся NCT07346586

Effect of Individualized Catheter Management on Early Removal After Rectal Cancer Surgery

Без фазы С лечением Urinary Catheters Rectal Cancer Urinary Retention

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Individualized Management Group, 24-Hour Removal Group, 48-Hour Removal Group.
Кому может быть актуально
Состояния в реестре: Urinary Catheters, Rectal Cancer, Urinary Retention. Базовые параметры: Без ограничений · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Effect of an Individualized Urinary Catheter Management Strategy on the Safety and Efficacy of Early Catheter Removal After Mid-Low Rectal Cancer Surgery: A Single-Center Randomized Controlled Trial

Обзор

This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer. Current clinical practice faces controversy regarding the optimal timing of catheter removal (24 hours vs. 48 hours) and lacks precise preventive measures for patients at high risk of postoperative acute urinary retention (AUR). To address these issues, this study is designed as a three-arm randomized controlled trial, directly comparing three management protocols: catheter removal at 24 hours postoperatively, catheter removal at 48 hours postoperatively, and an individualized strategy guided by a predictive model (i.e., preventive administration of tamsulosin to high-risk AUR patients prior to catheter removal). The primary endpoint is the rate of recatheterization within 7 days after the initial removal, with secondary endpoints comprehensively assessing urinary tract infections, voiding function, and postoperative complications. The ultimate goal is to provide high-quality evidence-based medical evidence to establish a precise and standardized clinical pathway for individualized postoperative catheter management.

Вмешательства

  • Поведенческое Individualized Management Group
    Participants assessed by the AUR risk prediction model immediately postoperatively. High-risk patients receive prophylactic tamsulosin until catheter removal. All patients have their catheter removed at 4:00 AM on postoperative day 1.
  • Поведенческое 24-Hour Removal Group
    Participants do not receive prophylactic tamsulosin. The urinary catheter is removed uniformly at 4:00 AM on postoperative day 1.
  • Поведенческое 48-Hour Removal Group
    Participants do not receive prophylactic tamsulosin. The urinary catheter is removed uniformly at 4:00 AM on postoperative day 2.

Первичные конечные точки

  • Rate of recatheterization within 7 days after the initial catheter removal [Срок оценки: Rate of recatheterization within 7 days after the initial catheter removal]
Вторичные конечные точки (5)
  • Incidence of Catheter-Associated Urinary Tract Infection (CAUTI). [Срок оценки: within 1 days after the initial catheter removal]
  • Time to First Successful Voiding after Catheter Removal [Срок оценки: within 1 days after the initial catheter removal]
  • Voiding function assessed by the ICIQ-SF questionnaires after catheter removal [Срок оценки: within 2 days after the initial catheter removal]
  • Voiding function assessed by the lPSS questionnaires after catheter removal [Срок оценки: within 2 days after the initial catheter removal]
  • Incidence, types, and severity (graded by Clavien-Dindo classification) of postoperative complications within 30 days. [Срок оценки: within 30 days postoperatively]

Критерии участия

Критерии включения

  • Patients with a preoperative pathological confirmation of rectal malignant tumor.
  • Preoperative colorectal CT or rectal MRI confirming that the lower edge of the tumor is located in the rectum within 10 cm from the anal verge (including rectal and anal canal lesions).
  • Patients scheduled to undergo laparoscopic or robot-assisted radical total mesorectal excision (TME).

Критерии исключения

  • History of previous abdominal surgery involving the rectum/sigmoid colon/left colon, bladder resection or partial resection, prostate surgery (in males), or hysterectomy (in females).
  • History of urethral trauma, intracranial surgery, spinal surgery, cerebral infarction with limb dysfunction, or Parkinson's disease.
  • Inability to void urethrally preoperatively due to any reason (e.g., ureteral puncture, ureterostomy).
  • Previously diagnosed overactive bladder syndrome, prior AUR or voiding dysfunction, or diabetic cystopathy.
  • Preoperative assessment indicating potential need for combined resection of other pelvic organs during surgery, including the bladder, prostate, uterus and cervix, or vagina (excluding simple adnexectomy in females).
  • Preoperative assessment indicating potential need for lateral pelvic lymph node dissection.
  • Preoperative renal insufficiency (serum creatinine level >133 μmol/L).
  • Patients undergoing emergency surgery.
  • Male patients with preoperative benign prostatic hyperplasia requiring medication.
  • Presence of indwelling ureteral stents, ureteral stenosis, or bilateral hydronephrosis.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Лечение

Центры проведения

Китай · 1 центр
  • The First Hospital of Jilin University — Changchun

Идентификаторы

NCT: NCT07346586 · ICCAUT-3

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗